Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 16, 2025 08:30 ET | Source: Vivani Medical, Inc.

Vivani Medical to Participate in Virtual Fireside Chat Hosted by H.C. Wainwright & Company

Portfolio of miniature, once or twice-yearly GLP-1 implants in development for chronic weight management and type 2 diabetes Vivani CEO Adam Mendelsohn, Ph.D. and CMO Lisa Porter, M.D. to...
April 15, 2025 08:30 ET | Source: Vivani Medical, Inc.

Vivani Medical and Okava Expand Collaboration to Develop OKV-119 for Dogs, Targeting Metabolic Health and Longevity

ALAMEDA, Calif. and SAN FRANCISCO, April 15, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing...
March 31, 2025 07:30 ET | Source: Vivani Medical, Inc.

Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Successful initial administration and full enrollment in first-in-human LIBERATE-1™ study of NPM-115 (exenatide implant) in obese and overweight subjects with top-line data expected in mid-2025 ...
March 27, 2025 07:32 ET | Source: Vivani Medical, Inc.

Vivani Medical Announces $8.25M Private Placement Equity Financing

Financing strengthens balance sheet, extending expected runway into the second quarter of 2026 Enables accelerated development of NPM-139, Company’s once or twice-yearly GLP-1 (semaglutide) implant...
March 26, 2025 07:30 ET | Source: Vivani Medical, Inc.

Vivani Medical Announces Positive Preclinical Weight Loss Data for NPM-139 Semaglutide Implant, with Potential for Once-Yearly Dosing

NanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study with NPM-139 (semaglutide implant) NPM-139 treatment resulted in nearly 20%...